Carmot Therapeutics Inc.

Roche has made a major advance in its bid to join Novo Nordisk and Eli Lilly at the top of the obesity tree by paying a whopping $1.65bn upfront fee to co-develop and co-commercialize Zealand’s closel

Big pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March. Ab

Throughout 2024, the acquisition of Catalent, one of the world’s biggest CDMOs, by Novo Holdings, the holding company for the global pharmaceutical giant Novo Nordisk, prompted much concern among big

Roche’s Favorable Stock Reaction There was no headline fanfare when Johnson & Johnson (J&J) reported its fourth-quarter 2024 results . While the announcement included the phrase “transformat